In the last trading session, 572.94 million shares of the Processa Pharmaceuticals Inc (NASDAQ:PCSA) were traded, and its beta was 1.36. Most recently the company’s share price was $0.26, and it changed around $0.03 or 15.50% from the last close, which brings the market valuation of the company to $3.10M. PCSA currently trades at a discount to its 52-week high of $3.10, offering almost -1092.31% off that amount. The share price’s 52-week low was $0.15, which indicates that the current value has risen by an impressive 42.31% since then. We note from Processa Pharmaceuticals Inc’s average daily trading volume that its 10-day average is 62.48 million shares, with the 3-month average coming to 4.64 million.
Processa Pharmaceuticals Inc stock received a consensus recommendation rating of Hold, based on a mean score of 2.00. If we narrow it down even further, the data shows that 0 out of 2 analysts rate the stock as a Sell; another 1 rate it as Overweight. Among the rest, 1 recommended PCSA as a Hold, whereas 0 deemed it a Buy, and 0 rated it as Underweight.
Processa Pharmaceuticals Inc (NASDAQ:PCSA) trade information
Instantly PCSA has showed a green trend with a performance of 15.50% at the end of last trading. The performance over the last five days has remained in the red territory. The rise to weekly highs of 0.7854 on recent trading dayincreased the stock’s daily price by 66.9%. The company’s shares are currently down -70.58% year-to-date, but still down -24.31% over the last five days. On the other hand, Processa Pharmaceuticals Inc (NASDAQ:PCSA) is 10.78% up in the 30-day period. We can see from the shorts that 0.75 million shares have been sold at a short interest cover period of 0.26 day(s).
The consensus price target as assigned by Wall Street analysts is $9, which translates to bulls needing to increase their stock price by 97.11% from its current value. Analyst projections state that PCSA is forecast to be at a low of $9 and a high of $9.
Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 22.65%. Processa Pharmaceuticals Inc earnings are expected to increase by 77.00% in 2025, but the outlook is positive 42.13% per year for the next five years.
PCSA Dividends
Processa Pharmaceuticals Inc’s next quarterly earnings report is expected to be released on 2025-May-08.
Processa Pharmaceuticals Inc (NASDAQ:PCSA)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 5.13% of Processa Pharmaceuticals Inc shares, and 1.44% of them are in the hands of institutional investors. The stock currently has a share float of 1.51%.
